Trials / Completed
CompletedNCT02955459
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
VNRX-5133-101/102: A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Venatorx Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion in healthy subjects. In part 1, subjects will receive a single dose of VNRX-5133; in part 2 subjects will receive VNRX-5133 for 7 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VNRX-5133 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2016-11-04
- Last updated
- 2017-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02955459. Inclusion in this directory is not an endorsement.